Compassionate Use of Beraprost Sodium 314d Modified Release (BPS-314d-MR) for Three Patients With Pulmonary Arterial Hypertension (PAH).

Trial Profile

Compassionate Use of Beraprost Sodium 314d Modified Release (BPS-314d-MR) for Three Patients With Pulmonary Arterial Hypertension (PAH).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Beraprost (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Expanded access
  • Most Recent Events

    • 31 Jan 2018 Planned end date changed from 1 Dec 2017 to 1 Dec 2019.
    • 31 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
    • 07 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top